Analyst Upgrade Sparks Buzz: Recent discussions on X about AbbVie (ABBV) have heated up following a notable analyst upgrade from a major financial institution, raising the stock’s price target significantly. Many users are expressing optimism about the potential upside, with some highlighting the company’s strong position in the pharmaceutical sector. The upgrade has fueled conversations about whether the stock could see further gains in the near term.
Pipeline and Portfolio Strength: Beyond the upgrade, there’s active chatter on X about AbbVie’s robust drug portfolio and promising pipeline, especially drugs like Rinvoq and Skyrizi as key growth drivers. Some discussions point to recent Phase 3 data readouts as a positive signal for future revenue streams. Investors on the platform seem intrigued by how these developments might counterbalance past challenges like patent cliffs.
Competitive Pressures Loom: However, not all talk is positive, as some X users are raising concerns about emerging competition in key therapeutic areas, with speculation about potential buyouts or licensing deals to stay ahead. There’s also mention of rival drugs that could challenge AbbVie’s market share, adding a layer of uncertainty to the discussion. This mix of hope and caution keeps the conversation dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
AbbVie Insider Trading Activity
AbbVie insiders have traded $ABBV stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- AZITA SALEKI-GERHARDT (EVP, CHIEF OPERATIONS OFFICER) sold 42,370 shares for an estimated $8,407,055
- NICHOLAS DONOGHOE (EVP, CHIEF BUS/STRAT OFFICER) has made 0 purchases and 2 sales selling 13,295 shares for an estimated $2,639,252.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AbbVie Revenue
AbbVie had revenues of $15.8B in Q3 2025. This is an increase of 9.1% from the same period in the prior year.
You can track ABBV financials on Quiver Quantitative's ABBV stock page.
AbbVie Congressional Stock Trading
Members of Congress have traded $ABBV stock 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 6 times. They made 3 purchases worth up to $45,000 on 10/30, 07/22, 06/17 and 3 sales worth up to $45,000 on 10/31, 10/30, 07/22.
- SENATOR JOHN BOOZMAN has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 08/22, 08/11.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 08/14.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 08/04.
- REPRESENTATIVE RITCHIE TORRES sold up to $15,000 on 07/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AbbVie Hedge Fund Activity
We have seen 1,926 institutional investors add shares of AbbVie stock to their portfolio, and 1,655 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 10,559,645 shares (+72.3%) to their portfolio in Q3 2025, for an estimated $2,444,980,203
- WELLINGTON MANAGEMENT GROUP LLP added 8,646,424 shares (+457.4%) to their portfolio in Q3 2025, for an estimated $2,001,993,012
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 3,134,454 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $725,751,479
- CAPITAL INTERNATIONAL INVESTORS removed 2,947,890 shares (-21.6%) from their portfolio in Q3 2025, for an estimated $682,554,450
- NORGES BANK removed 1,992,983 shares (-7.9%) from their portfolio in Q2 2025, for an estimated $369,937,504
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,830,775 shares (-53.6%) from their portfolio in Q3 2025, for an estimated $423,897,643
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 1,771,612 shares (+37.5%) to their portfolio in Q3 2025, for an estimated $410,199,042
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AbbVie Government Contracts
We have seen $371,294 of award payments to $ABBV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- IMPLANT: $35,788
- 4567253744!NATRELLE TE SMOOTH 133S-SV-13-T: $33,629
- PROSTHETIC ORDER - IMPLANT ITEMS: $15,758
- PROSTHETIC ORDER - BREAST IMPLANTS: $14,124
- 4567881995!NATRELLE TE SMOOTH 133S-MV-15-T: $13,170
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AbbVie Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HSBC issued a "Buy" rating on 12/10/2025
- Guggenheim issued a "Buy" rating on 10/20/2025
- Piper Sandler issued a "Overweight" rating on 10/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/15/2025
- BMO Capital issued a "Outperform" rating on 09/12/2025
To track analyst ratings and price targets for AbbVie, check out Quiver Quantitative's $ABBV forecast page.
AbbVie Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 15 analysts offer price targets for $ABBV in the last 6 months, with a median target of $251.0.
Here are some recent targets:
- Rajesh Kumar from HSBC set a target price of $265.0 on 12/10/2025
- Ashwani Verma from UBS set a target price of $220.0 on 11/07/2025
- David Amsellem from Piper Sandler set a target price of $289.0 on 11/05/2025
- Chris Schott from JP Morgan set a target price of $260.0 on 11/03/2025
- Geoff Meacham from Citigroup set a target price of $235.0 on 11/03/2025
- Vamil Divan from Guggenheim set a target price of $242.0 on 10/20/2025
- Gary Nachman from Raymond James set a target price of $250.0 on 10/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
